ReviewLupus2010
Antiphospholipid syndrome and the brain in pediatric and adult patients.
Review in Lupus, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 55 citations in OpenAlex.
- Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases.International journal of hematology · 2013Trial
- Pulmonary Endarterectomy in Patients with Antiphospholipid Syndrome-Associated Chronic Thromboembolic Pulmonary Hypertension.Anatolian journal of cardiology · 2022Article
- Primary antiphospholipid syndrome in pediatrics: beyond thrombosis. Report of 32 cases and review of the evidence.Pediatric rheumatology online journal · 2022Review
- Hypoxic-ischemic injury causes functional and structural neurovascular degeneration in the juvenile mouse retina.Scientific reports · 2021Article
- Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome.Journal of clinical medicine · 2021Review
- Update on Antiphospholipid Syndrome: Ten Topics in 2017.Current rheumatology reports · 2018Review
- Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?Immunologic research · 2017Review
- Pediatric antiphospholipid syndrome.Current rheumatology reports · 2015Review
- Neonatal stroke associated with de novo antiphospholipid antibody and homozygous 1298C/C methylenetetrahydrofolate reductase mutation.BMJ case reports · 2012Article
- Statins for COPD: a challenge to conventional beliefs?Primary care respiratory journal : journal of the General Practice Airways Group · 2012Article
- Frequent association of thrombophilia in cerebral venous sinus thrombosis.International journal of hematology · 2012Article
- The management of stroke in antiphospholipid syndrome.Current rheumatology reports · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The most common neurological manifestations of antiphospholipid syndrome (APS) in all age-groups include stroke and transient ischemic attacks due to arterial thromboses and cerebral ischemia. Antiphospholipid antibodies may cause additional non-criteria neurological impairments through vascular, neuroinflammatory and direct neuronal effects. Anti-aggregant or anticoagulant therapies are indicated for APS-related ischemic strokes. Treatment regimens for asymptomatic antibody-positive patients and those with refractory or recurrent disease remain controversial. There is scant literature on the epidemiology and therapy of neurological APS manifestations in pediatric patients. Assessments of modifiable cardiovascular and inherited thrombophilia risk factors are essential in patients with APS. There may be a role for novel neuroimaging modalities in quantifying APS-related microstructural brain damage. The clinical utility of statins, antimalarials, angiotensin-converting enzyme inhibitors, and thrombin inhibitors warrant further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.